opc 28326 has been researched along with Left Ventricular Dysfunction in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiwara, H; Fujiwara, T; Goto, K; Hashimoto, A; Kanamori, H; Kawasaki, M; Minatoguchi, S; Miyakoda, G; Nagashima, K; Nakagawa, M; Ogino, A; Okada, H; Takemura, G; Tsujimoto, A; Yabuuchi, Y | 1 |
1 other study(ies) available for opc 28326 and Left Ventricular Dysfunction
| Article | Year |
|---|---|
OPC-28326, a selective peripheral vasodilator with angiogenic activity, mitigates postinfarction cardiac remodeling.
Topics: Angiogenesis Inducing Agents; Aniline Compounds; Animals; Cell Proliferation; Heart; Ki-67 Antigen; Mice; Myocardial Infarction; Myocardium; Myofibroblasts; Nitric Oxide Synthase Type III; Piperidines; Proto-Oncogene Proteins c-akt; Survival Rate; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Remodeling | 2015 |